II

Global Huntington's Disease Treatment Market Size, Share & Trends Analysis Report 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 14, 2023
General Health, Science, Health, Research, HD, Huntington's disease, Drug development, Prevalence, Dysphagia, SRX246, HTT, Somnolence, Senior counsel, Disease, ZFP, Quality of life, Brain, Toxicity, II, Compound annual growth rate, Aggression, Investment, Patient, Palliative care, Growth, Irritation, Treatment, Symptomatic treatment, HRQOL, Pharmaceutical industry, Nursing, Vaccine

The "Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Treatment, Disease-Modifying Therapies), By End use, By Region, And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Treatment, Disease-Modifying Therapies), By End use, By Region, And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.
  • The anticipated growth of the global Huntington's disease treatment market is poised to make a significant impact, with projections indicating it will reach a substantial USD 1,871.2 million by 2030, as detailed in this comprehensive report.
  • Huntington's disease, a rare inherited neurodegenerative condition, exerts its impact across multiple generations, severely affecting individuals between the ages of 30 and 50.
  • The symptomatic treatment segment accounted for the largest revenue share in 2022 owing to the product availability and patent protection.

AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease

Retrieved on: 
Tuesday, September 12, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Alpha-synuclein, PD, Centrifugation, Celsius, Neurodegenerative disease, The Michael J. Fox Foundation, Tears, II, Organization, Bicinchoninic acid assay, Parkinson's disease, Synuclein, Patient, Freezing, Lactoferrin, Diagnosis, III, Alzheimer's disease, Medical imaging, Palladium

Fox Foundation shows that the presence of abnormal alpha-synuclein was detected in an astonishing 93% of people with Parkinson’s who participated in the study.

Key Points: 
  • Fox Foundation shows that the presence of abnormal alpha-synuclein was detected in an astonishing 93% of people with Parkinson’s who participated in the study.
  • These findings suggest a crucial role for α-synuclein in therapeutic development, both in identifying pathologically defined subgroups of people with Parkinson's disease and establishing biomarker-defined at-risk cohorts.
  • Total tear protein content is first quantified using a bicinchoninic acid assay followed by alpha-Synuclein using a bulky plate reader.
  • AXIM is already marketing a lactoferrin assay, which may be used in conjunction with the newly developed novel Synuclein test.

Trigeminal Neuralgia Drug Pipeline Research Report 2023: Comprehensive Insights on 10 Companies and 10 Pipeline Drugs Featuring Biogen, Biohaven Pharmaceuticals, Noema Pharma, & Pfizer - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 12, 2023
Health, Pharmaceutical, Biogen, II, Mergers and acquisitions, Trigeminal neuralgia, Discovery, Therapy, III, News, Rimegepant, Nursing, Pharmaceutical industry

The "Trigeminal Neuralgia- Pipeline Insight, 2023" report offers comprehensive insights into the Trigeminal Neuralgia pipeline landscape, featuring information on more than 10 companies and over 10 pipeline drugs.

Key Points: 
  • The "Trigeminal Neuralgia- Pipeline Insight, 2023" report offers comprehensive insights into the Trigeminal Neuralgia pipeline landscape, featuring information on more than 10 companies and over 10 pipeline drugs.
  • Leading companies and academic institutions are dedicated to addressing challenges and exploring opportunities that can shape the future of Trigeminal Neuralgia research and development.
  • The therapies currently in development focus on innovative approaches to enhance the treatment and management of Trigeminal Neuralgia.
  • This segment of the report provides insights about the different Trigeminal Neuralgia drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.

OmniSync Awarded a Contract by The Under Secretary of Defense, Research and Engineering to Provide AI-Powered Research Impact Analysis Capabilities

Retrieved on: 
Thursday, September 7, 2023
Defense Technical Information Center, Army, United States Department of Defense, Intelligence, Research, USD, Government, Science, II, Organization, DOD, DTIC, Investment, SAN, Navy, U.S. Department of Defense Strategy for Operating in Cyberspace, The, DAF, Artificial intelligence, Air force, Ecosystem, R, AFWERX, Under Secretary of Defense for Research and Engineering, Medical device, Defense, Engineering

OmniSync will use these capabilities to help DTIC and the wider DOD community understand investments, overlaps, impact, and future potential of various R&D projects being conducted across the Department.

Key Points: 
  • OmniSync will use these capabilities to help DTIC and the wider DOD community understand investments, overlaps, impact, and future potential of various R&D projects being conducted across the Department.
  • OmniSync began in 2019 by assisting commercial innovators from US-based startups in getting funded by the government for developing their technologies, through our TurboSBIR platform.
  • We then expanded organically into innovation market research, through TurboInnovate, helping innovation seekers find suitable technologies and research landscapes.
  • This SBIR Phase II extension award to OmniSync follows the Phase I and II SBIR contracts that OmniSync was awarded through the AFWERX program from Department of Air Force (DAF).

ERI to Reposition Geographic Footprint to Accommodate Continued Growth of ITAD and E-Waste Recycling Services

Retrieved on: 
Wednesday, September 6, 2023
Recycling, Consumer Electronics, Environment, Technology, Sustainability, Green Technology, Hardware, Aurora, ERI, Electronics, Overalls, SOC, Carbon, Privacy, Electronic waste, II, Ellen, Organization, Collection, MacArthur, Growth, ESG

ERI , the nation’s largest fully integrated IT and electronics asset disposition (ITAD) provider and cybersecurity-focused hardware destruction company, has announced that it will recalibrate its geographic footprint to accommodate demand, customer requests and steadily continued growth.

Key Points: 
  • ERI , the nation’s largest fully integrated IT and electronics asset disposition (ITAD) provider and cybersecurity-focused hardware destruction company, has announced that it will recalibrate its geographic footprint to accommodate demand, customer requests and steadily continued growth.
  • As part of the recalibration, it will open three larger, state-of-the-art ITAD and e-waste recycling centers in 2024 and close its smallest facility in Aurora, Colorado.
  • Earlier this year, ERI opened a new recycling facility in Goodyear, Arizona (near Phoenix) and saw its biggest sales growth quarter in company history.
  • “We’re excited about what the future holds on a national level for ERI,” said ERI’s Co-Founder, Chairman and CEO, John Shegerian.

Marsh McLennan Announces Pricing of $1.6 Billion Senior Notes Offering

Retrieved on: 
Wednesday, September 6, 2023
Consulting, Professional Services, Insurance, Finance, Deutsche Bank, Telephone, Debt-to-GDP ratio, BofA Securities, J.P. Morgan & Co., Sale, MMC, II, McLennan, ATTN:, III, Security (finance), NYSE, Broadridge Financial Solutions, Note

Marsh McLennan (NYSE: MMC) (the “Company”) announced today that it has priced $600,000,000 aggregate principal amount of its 5.400% Senior Notes due 2033 (the “2033 Notes”) and $1,000,000,000 aggregate principal amount of its 5.700% Senior Notes due 2053 (the “2053 Notes” and, together with the 2033 Notes, the “Notes”).

Key Points: 
  • Marsh McLennan (NYSE: MMC) (the “Company”) announced today that it has priced $600,000,000 aggregate principal amount of its 5.400% Senior Notes due 2033 (the “2033 Notes”) and $1,000,000,000 aggregate principal amount of its 5.700% Senior Notes due 2053 (the “2053 Notes” and, together with the 2033 Notes, the “Notes”).
  • The Company intends to use the net proceeds from the Notes offering for general corporate purposes.
  • The closing of the Notes offering is expected to occur on September 11, 2023, subject to the satisfaction of certain customary closing conditions.
  • The offering and sale of the Notes are being made by means of a prospectus supplement and an accompanying base prospectus related to the offering.

Institutional Investor Launches 2023 Developed Europe, 2023 UK Small & Midcap and 2023 Emerging Emea Research Rankings

Retrieved on: 
Wednesday, September 6, 2023
Kepler, Bank of America, Marketing, Virginia Intermont College, CaixaBank, Investec, BofA Securities, Emerging, ODDO BHF, Credit Suisse, II, JB, Acquisition, SEB, UBS, Environment, Institutional Investor, Morgan Stanley, Markets in Financial Instruments Directive 2014, Nordic, Mediobanca, ESN, Best, Deutsche Bank, BNP Paribas, J. P. Morgan, Human, HSBC, ING, Citigroup, Direct Corporate Access, ABG Sundal Collier, RBC, Carnegie Investment Bank, Stifel, Banca Akros, Wood, Commerzbank, Small, Institution, Société Générale, FTSE Developed Europe Index, Renewable energy, Cryptocurrency, Security (finance), Financial adviser, Bank, Jefferies, Extel, Research, Barclays

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Institutional Investor Research (II Research) surveys are the leading provider of market sentiment in the financial industry. Research budgets remain flat and asset managers are using fewer analysts, but demand for bespoke opinion means that close client relationships and “trusted source” status becomes more important than ever before. With MiFID regulations potentially being rolled back across Europe and UK, the focus on the provision of quality research advisory services may result in a more competitive environment and we may see an increase in research teams across the industry.

Key Points: 
  • NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Institutional Investor Research (II Research) surveys are the leading provider of market sentiment in the financial industry.
  • The Leaders’ Board remains intensely competitive, with seven companies competing for the honour of being rated best research house.
  • The 2023 UK Small & Midcap results reflect the opinions of 359 portfolio managers and analysts at 233 institutions.
  • The Best UK Small & Midcap Broker award represents an aggregate of all 20 research categories, plus the Sales, Corporate Access and Corporate Broking categories.

Bild Expo Is Live: Join Us at Gear Expo for New Product Announcements and Educational Presentation

Retrieved on: 
Wednesday, September 6, 2023
Hardware, Photography, Audio, Video, Consumer Electronics, Technology, Maker, Eclipse, Carbon, Well, MT, Javits Center, Life, APS, ENG, GoPro, Summicron, B&H, Special edition, Temperature, Canon RF lens mount, ARRI, Titanium, II, Projection, MacOS, Sonos, SanDisk, Collection, Bluetooth, Sport, Data-rate units, Transport, Leica, FIZ, L3, COB, CFexpress, Lowepro, TB, EF, Element, Nanook, LED, RAID 1, Barndoor skate, Specific, Iris, Canon EF lens mount, Carbon-fiber-reinforced polymers, GM2, EA, Shape, CCT, Multimedia, AC, ANSI, Tablet, Gold, Sigma, Hertz, CompactFlash, Traveller Alien Module 8: Darrians, Lensbaby, L1, Light-emitting diode, Sony, Lens, Super 35, Traveler, SKB, Corrosion, Ecosystem, RGB, BIONZ, Television, Computer data storage, Camera, Video game, Telescopic sight, Cassette tape, Daystar, L2, T16

Angelbird’s other offering for B&H’s 50th-anniversary celebration is the 512GB AV PRO CFexpress 2.0 Type B SE Memory Card .

Key Points: 
  • Angelbird’s other offering for B&H’s 50th-anniversary celebration is the 512GB AV PRO CFexpress 2.0 Type B SE Memory Card .
  • Designer of high-end cine lenses from France, Angenieux has announced the EZ-3 Series Convertible Super 35 and Full-Frame/VistaVision zoom lens.
  • Maker of ergonomic carrying solutions for long shoots, BlackRapid is releasing the special 50th-anniversary-edition Curve Breathe Camera Strap Bundle .
  • The bundle includes a curve breathe camera strap, an underarm stabilizer, a safety tether II, a Lockstar II, and two FR-5 FastenRs.

Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference

Retrieved on: 
Tuesday, September 5, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ketan, Pharma, Naloxone, Oxycodone, Food and Drug Administration, Opioid use disorder, ADHD, DSM-IV codes, OUD, VAS, FQ, Physical dependence, II, Pain, Visual analogue scale, NOP, Patient, Risk, MOP, Neuropathic pain, Pain management, Addiction, Drug, HAP, FDA, Tramadol, Food, Pharmaceutical industry, Tris

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids.

Key Points: 
  • Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids.
  • The findings will be shared on Thursday, September 7, in a poster presentation at the 2023 PAINWeek conference in Las Vegas.
  • Study participants randomly received a single dose of placebo, cebranopadol 600 μg, cebranopadol 1000 μg, tramadol IR 600 mg or oxycodone IR 40 mg.
  • The difference between the good effects and bad effects of drugs have been linked to their abuse potential.

Cosmetics & Beauty Expo Osong Korea 2023 to be held from Oct 17 to 21

Retrieved on: 
Monday, September 4, 2023
Entertainment, Fitness & Nutrition, Events, Concerts, Other Health, Food, Beverage, Other Education, Health, Cosmetics, Retail, Education, Perfume, Ministry of Food and Drug Safety, Multimedia, II, Organization, Connecticut Business Hall of Fame, Ministry, Beauty, Poster, Corporation, LG, Everett Inbody, K-Beauty, Beauty salon, Tourism, Auction, Nightclub, Osong station

Now in its tenth year, the Cosmetics & Beauty Expo Osong Korea 2023 will be held in Osong Bio Valley from October 17th through 21st.

Key Points: 
  • Now in its tenth year, the Cosmetics & Beauty Expo Osong Korea 2023 will be held in Osong Bio Valley from October 17th through 21st.
  • View the full release here: https://www.businesswire.com/news/home/20230823045941/en/
    2023 Cosmetics & Beauty Expo Osong Korea will be held on Oct 17 to 21 (Poster: Osong Bio-Promotion Foundation)
    200 renowned domestic companies including LG H&H and Pion-Tech as well as around 700 buyers from Korea and abroad are going to participate, and more than 100,000 visitors to the expo are expected.
  • The Cosmetics & Beauty Expo Osong Korea 2023 is the dynamic site where K-Beauty is emerging anew, making it the best place to take a glimpse into all of Korea’s leading cosmetic products.
  • The event is held under the slogan of “K-Beauty in the World: Discover It in Osong”, and it has been designed as “beauty unboxing” from the context of enabling the entire world to receive the gift of beauty in Osong.